


We Claim:

1. A compound of formula (I)



wherein

- 5 R^1 is selected from the group consisting of hydrogen, hydroxy, A, -O-A, C(O)-A and $-SO_2$ -A;
- n is an integer from 0 to 2;
- each R^2 is independently selected from the group consisting of hydroxy, carboxy, halogen, -A, -O-A, -C(O)-A, -C(O)O-A, amino, alkylamino, dialkylamino, cyano, aminocarbonyl, alkylaminocarbonyl, dialkylaminocarbonyl, -SH, -S-A, -SO-A, $-SO_2$ -A, $-SO_2$ -NH₂, $-SO_2$ -NH(alkyl) and $-SO_2$ -N(alkyl)₂;
- 10 m is an integer from 0 to 2;
- each R^3 is independently selected from the group consisting of -A, -O-A, -S-A, -NH-A, -N(A)₂ and -C(O)-A;
- 15 p is an integer from 1 to 2;
- each R^4 is independently selected from the group consisting of hydroxy, carboxy, cyano, -A, alkenyl, -alkenyl-A, alkynyl, -alkynyl-A, -O-A, -NH₂, NH(A), -N(A)₂, -N(A)-C(O)-A, -NH-C(O)-A, -C(O)-N(A)₂, -C(O)-NH₂, -C(O)-NH-A, $-SO_2$ -N(A)₂, $-SO_2$ -NH(A), $-SO_2$ -NH₂, -N(A)- SO_2 -A, -NH- SO_2 -A, -C(O)O-A, -OC(O)H and -OC(O)-A;
- 20 alternatively, when p is 2, two R^4 groups may be taken together as oxo or =N(OH);
- q is an integer from 0 to 2;
- each R^5 is independently selected from the group consisting of hydroxy, carboxy, halogen, alkyl, alkoxy, cycloalkyl and -C(O)-A; wherein the alkyl group is optionally substituted with one or more substituents independently selected from halogen, hydroxy, carboxy or alkoxy;

wherein each A is independently selected from the group consisting of alkyl, aryl, aralkyl, cycloalkyl, heteroaryl and heterocycloalkyl; wherein the aryl, aralkyl, cycloalkyl, heteroaryl or heterocycloalkyl group is optionally substituted with one or more substituents independently selected from halogen, hydroxy, 5 carboxy, lower alkyl, lower alkoxy, nitro, cyano, amino, lower alkylamino or di(lower alkyl)amino;

or a pharmaceutically acceptable salt thereof.

2. A compound as in Claim 1 wherein

10 R¹ is selected from the group consisting of hydrogen, hydroxy, A, -O-A, C(O)-A and -SO₂-A;

n is an integer from 0 to 1;

each R² is independently selected from the group consisting of carboxy, halogen, -A, -C(O)-A, -C(O)O-A, cyano, -S-A, -SO-A, -SO₂-A, -SO₂-NH₂, -SO₂-

15 NH(alkyl) and -SO₂-N(alkyl)₂;

m is an integer from 0 to 1;

each R³ is independently selected from the group consisting of -A, -O-A, -S-A, -NH-A and -C(O)-A;

p is an integer from 1 to 2;

20 R⁴ is selected from the group consisting of hydroxy, -NH₂, -NH(A), -N(A)₂, -C(O)NH₂, -C(O)-NH(A), -SO₂-NH₂, -SO₂-NH(A) and -OC(O)-A, when the R⁴ is in a β-orientation;

R⁴ is selected from the group consisting of hydroxy, carboxy, cyano, -A, alkenyl, -alkenyl-A, alkynyl, -alkynyl-A, -O-A, -NH₂, -NH(A), -N(A)₂, -N(A)-C(O)-A, -NH-C(O)-A, -C(O)-N(A)₂, -C(O)-NH₂, -C(O)-NH-A, -SO₂-N(A)₂, -SO₂-NH(A), 25 -SO₂-NH₂, -N(A)-SO₂-A, -NH-SO₂-A, -C(O)O-A, -OC(O)H and -OC(O)-A, when the R⁴ is in an α-orientation;

alternatively, when p is 2, two R⁴ groups may be taken together as oxo or =N(OH);

30 q is an integer from 0 to 1;

R⁵ is selected from the group consisting of carboxy, halogen, lower alkyl, and -C(O)-A; wherein the alkyl group is optionally substituted with one to two substituents independently selected from halogen, hydroxy, carboxy or alkoxy;

wherein each A is independently selected from the group consisting of
5 alkyl, aryl, aralkyl, cycloalkyl, heteroaryl and heterocycloalkyl; wherein the aryl, aralkyl, cycloalkyl, heteroaryl or heterocycloalkyl group is optionally substituted with one to two substituents independently selected from halogen, hydroxy, carboxy, lower alkyl, lower alkoxy, nitro, cyano, amino, lower alkylamino or di(lower alkyl)amino;
10 or a pharmaceutically acceptable salt thereof.

3. A compound as in Claim 2 wherein


R¹ is selected from the group consisting of hydrogen and -SO₂-alkyl;
n is 0;
15 m is 0;
p is an integer from 1 to 2;
R⁴ is selected from the group consisting of hydroxy and -O-C(O)-alkyl;
wherein the alkyl portion of the -O-C(O)-alkyl group is optionally substituted with a carboxy group;
20 alternatively when p is 2, two R⁴ groups are taken together as oxo;
q is 0;
or a pharmaceutically acceptable salt thereof.

4. A compound as in Claim 3 wherein

25 R¹ is selected from the group consisting of hydrogen and -SO₂-CH₃;
n is 0;
m is 0;
p is an integer from 1 to 2;
R⁴ is selected from the group consisting of hydroxy and -O-C(O)-n-butyl
30 and -O-C(O)-CH₂CH₂CH₂CH₂-CO₂H;
alternatively when p is 2, two R⁴ groups are taken together as oxo;
q is 0;

or a pharmaceutically acceptable salt thereof.

5. A compound of the formula (II)



5 wherein

- R¹ is selected from the group consisting of hydrogen, hydroxy, A, -O-A, C(O)-A and -SO₂-A;
- n is an integer from 0 to 2;
- each R² is independently selected from the group consisting of hydroxy, carboxy, halogen, -A, -O-A, -C(O)-A, -C(O)O-A, amino, alkylamino, dialkylamino, cyano, aminocarbonyl, alkylaminocarbonyl, dialkylaminocarbonyl, -SH, -S-A, -SO-A, -SO₂-A, -SO₂-NH₂, -SO₂-NH(alkyl) and -SO₂-N(alkyl)₂;
- m is an integer from 0 to 2;
- each R³ is independently selected from the group consisting of -A, -O-A, -S-A, -NH-A, -N(A)₂ and -C(O)-A;
- p is an integer from 1 to 2;
- each R⁴ is independently selected from the group consisting of hydroxy, carboxy, cyano, -A, alkenyl, -alkenyl-A, alkynyl, -alkynyl-A, -O-A, -NH₂, NH(A), -N(A)₂, -N(A)-C(O)-A, -NH-C(O)-A, -C(O)-N(A)₂, -C(O)-NH₂, -C(O)-NH-A, -SO₂-N(A)₂, -SO₂-NH(A), -SO₂-NH₂, -N(A)-SO₂-A, -NH-SO₂-A, -C(O)O-A, -OC(O)H and -OC(O)-A;
- alternatively, when p is 2, two R⁴ groups may be taken together as oxo or =N(OH);
- q is an integer from 0 to 2;
- each R⁵ is independently selected from the group consisting of hydroxy, carboxy, halogen, alkyl, alkoxy, cycloalkyl and -C(O)-A; wherein the alkyl group

is optionally substituted with one or more substituents independently selected from halogen, hydroxy, carboxy or alkoxy;

wherein each A is independently selected from the group consisting of alkyl, aryl, aralkyl, cycloalkyl, heteroaryl and heterocycloalkyl; wherein the aryl, aralkyl, cycloalkyl, heteroaryl or heterocycloalkyl group is optionally substituted with one or more substituents independently selected from halogen, hydroxy, carboxy, lower alkyl, lower alkoxy, nitro, cyano, amino, lower alkylamino or di(lower alkyl)amino;

or a pharmaceutically acceptable salt thereof.

10

6. A compound as in Claim 1 wherein

R¹ is selected from the group consisting of hydrogen, hydroxy, A, -O-A, C(O)-A and -SO₂-A;

n is an integer from 0 to 1;

15

each R² is independently selected from the group consisting of carboxy, halogen, -A, -C(O)-A, -C(O)O-A, cyano, -SO-A, -SO₂-A, -SO₂-NH₂, -SO₂-NH(alkyl) and -SO₂-N(alkyl)₂;

m is an integer from 0 to 1;

20

each R³ is independently selected from the group consisting of -A, -O-A, -S-A, -NH-A and -C(O)-A;

p is an integer from 1 to 2;

R⁴ is selected from the group consisting of hydroxy, -NH₂, -NH(A), -N(A)₂, -C(O)NH₂, -C(O)-NH(A), -SO₂-NH₂, -SO₂-NH(A) and -OC(O)-A, when the R⁴ is in a β-orientation;

25

R⁴ is selected from the group consisting of hydroxy, carboxy, cyano, -A, alkenyl, -alkenyl-A, alkynyl, -alkynyl-A, -O-A, -NH₂, -NH(A), -N(A)₂, -N(A)-C(O)-A, -NH-C(O)-A, -C(O)-N(A)₂, -C(O)-NH₂, -C(O)-NH-A, -SO₂-N(A)₂, -SO₂-NH(A), -SO₂-NH₂, -N(A)-SO₂-A, -NH-SO₂-A, -C(O)O-A, -OC(O)H and -OC(O)-A, when the R⁴ is in an α-orientation;

30

alternatively, when p is 2, two R⁴ groups may be taken together as oxo or =N(OH);

q is an integer from 0 to 1;

R^5 is selected from the group consisting of carboxy, halogen, lower alkyl, and $-C(O)-A$; wherein the alkyl group is optionally substituted with one to two substituents independently selected from halogen, hydroxy, carboxy or alkoxy;

wherein each A is independently selected from the group consisting of
5 alkyl, aryl, aralkyl, cycloalkyl, heteroaryl and heterocycloalkyl; wherein the aryl, aralkyl, cycloalkyl, heteroaryl or heterocycloalkyl group is optionally substituted with one to two substituents independently selected from halogen, hydroxy, carboxy, lower alkyl, lower alkoxy, nitro, cyano, amino, lower alkylamino or di(lower alkyl)amino;
10 or a pharmaceutically acceptable salt thereof.

7. A compound as in Claim 6 wherein

R^1 is selected from the group consisting of hydrogen and $-SO_2$ -alkyl;
n is an integer from 0 to 1;
15 R^2 is selected from the group consisting of $-S-(alkyl)$;
m is 0;
p is an integer from 1 to 2;
 R^4 is selected from the group consisting of hydroxy, alkynyl and $-O-C(O)-(alkyl)$;
20 alternatively, when p is 2, two R^4 groups are taken together as oxo;
q is 0;
or a pharmaceutically acceptable salt thereof.

8. A compound as in Claim 7 wherein

25 R^1 is selected from the group consisting of hydrogen and $-SO_2-CH_3$;
n is an integer from 0 to 1;
 R^2 is $-S-CH_3$;
m is 0;
p is an integer from 1 to 2;
30 R^4 is selected from the group consisting of hydroxy, ethynyl and $-OC(O)-n-butyl$;
alternatively, when p is 2, two R^4 groups are taken together as oxo;

q is 0;
or a pharmaceutically acceptable salt thereof.

9. A pharmaceutical composition comprising a pharmaceutically acceptable carrier and a compound of Claim 1.
5
10. A pharmaceutical composition made by mixing a compound of Claim 1 and a pharmaceutically acceptable carrier.
- 10 11. A process for making a pharmaceutical composition comprising mixing a compound of Claim 1 and a pharmaceutically acceptable carrier.
12. A method of treating a disorder mediated by an estrogen receptor, in a subject in need thereof comprising administering to the subject a therapeutically effective amount of the compound of Claim 1.
15
13. The method of Claim 12, wherein the disorder mediated by an estrogen receptor is selected from the group consisting of hot flashes, vaginal dryness, osteopenia, osteoporosis, hyperlipidemia, loss of cognitive function, degenerative brain diseases, cardiovascular diseases, cerebrovascular diseases, cancer of the breast tissue, hyperplasia of the breast tissue, cancer of the endometrium, hyperplasia of the endometrium, cancer of the cervix, hyperplasia of the cervix, cancer of the prostate, benign prostatic hyperplasia, endometriosis, uterine fibroids, osteoarthritis and contraception.
20
- 25 14. The method of Claim 13, wherein the disorder mediated by an estrogen receptor is selected from the group consisting of osteoporosis, hot flashes, vaginal dryness, breast cancer and endometriosis.
- 30 15. A method of treating a disorder mediated by an estrogen receptor in a subject in need thereof comprising administering to the subject a therapeutically effective amount of the composition of Claim 10.

16. A method of contraception comprising co-therapy with a therapeutically effective amount of a compound as in Claim 1 and a progestogen or a progestogen antagonist.

5

17. A pharmaceutical composition comprising a pharmaceutically acceptable carrier and a compound of Claim 5.

10 18. A pharmaceutical composition made by mixing a compound of Claim 5 and a pharmaceutically acceptable carrier.

19. A process for making a pharmaceutical composition comprising mixing a compound of Claim 5 and a pharmaceutically acceptable carrier.

15 20. A method of treating a disorder mediated by an estrogen receptor, in a subject in need thereof comprising administering to the subject a therapeutically effective amount of the compound of Claim 5.

21. The method of Claim 21, wherein the disorder mediated by an estrogen receptor is selected from the group consisting of hot flashes, vaginal dryness, osteopenia, osteoporosis, hyperlipidemia, loss of cognitive function, degenerative brain diseases, cardiovascular diseases, cerebrovascular diseases, cancer of the breast tissue, hyperplasia of the breast tissue, cancer of the endometrium, hyperplasia of the endometrium, cancer of the cervix, 25 hyperplasia of the cervix, cancer of the prostate, benign prostatic hyperplasia, endometriosis, uterine fibroids, osteoarthritis and contraception.

22. The method of Claim 21, wherein the disorder mediated by an estrogen receptor is selected from the group consisting of osteoporosis, hot flashes, vaginal dryness, breast cancer and endometriosis.

23. A method of treating a disorder mediated by an estrogen receptor in a subject in need thereof comprising administering to the subject a therapeutically effective amount of the composition of Claim 18.
- 5 24. A method of contraception comprising co-therapy with a therapeutically effective amount of a compound as in Claim 5 and a progestogen or a progestogen antagonist.
- 10 25. A method of contraception comprising co-therapy with a therapeutically effective amount of a compound of formula (II) and a progestogen or a progestogen antagonist.